Free Cash Flow Chart

View Free Cash Flow for GERN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Free Cash Flow Chart
Start Trial

Historical Free Cash Flow Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -114.76M
March 31, 2026 -126.13M
December 31, 2025 -110.95M
September 30, 2025 -132.68M
June 30, 2025 -178.14M
March 31, 2025 -204.41M
December 31, 2024 -219.30M
September 30, 2024 -216.50M
June 30, 2024 -208.58M
March 31, 2024 -184.70M
December 31, 2023 -168.57M
September 30, 2023 -162.89M
June 30, 2023 -141.61M
March 31, 2023 -140.52M
December 31, 2022 -127.81M
September 30, 2022 -114.76M
June 30, 2022 -107.94M
March 31, 2022 -97.04M
December 31, 2021 -95.76M
September 30, 2021 -86.12M
June 30, 2021 -78.64M
March 31, 2021 -73.41M
December 31, 2020 -67.05M
September 30, 2020 -64.88M
June 30, 2020 -61.67M
Date Value
March 31, 2020 -57.84M
December 31, 2019 -44.24M
September 30, 2019 -36.80M
June 30, 2019 -30.71M
March 31, 2019 -26.44M
December 31, 2018 -21.02M
September 30, 2018 -22.40M
June 30, 2018 -20.67M
March 31, 2018 -20.62M
December 31, 2017 -20.56M
September 30, 2017 -16.80M
June 30, 2017 -18.93M
March 31, 2017 -20.13M
December 31, 2016 -18.43M
September 30, 2016 -23.08M
June 30, 2016 -21.37M
March 31, 2016 -22.07M
December 31, 2015 -24.20M
September 30, 2015 9.532M
June 30, 2015 9.965M
March 31, 2015 11.01M
December 31, 2014 9.219M
September 30, 2014 -25.89M
June 30, 2014 -27.13M
March 31, 2014 -29.93M

Free Cash Flow Range, Past 5 Years

View Free Cash Flow Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Free Cash Flow Benchmarks

View Free Cash Flow Benchmarks
Start Trial
Precigen, Inc. -115.22M
Editas Medicine, Inc. -120.55M
Agenus, Inc. -98.50M
Amgen, Inc. 10.18B
Anika Therapeutics, Inc. 0.562M